Molecular combing technology Facts & figures Lucia Cinque, …...oncogenetic testing market, projected to grow to $10B - $25B by 2020, with Prediction/Detection tests expected to account

Investor PresentationNovember 2015

A pioneering approach

for genomic analysis

DISCLAIMER

• This document has been prepared by Genomic Vision (the "Company") and is provided for information purposes only. This document does not purport to containcomprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is requiredto publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris. No reliance may be placed for any purposeswhatsoever on the information or opinions contained in this document or on its accuracy or completeness.

• This presentation does not constitute an offer to sell, a solicitation of, or an invitation to subscribe for or to buy, securities of Genomic Vision in any jurisdiction

• The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified oramended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions containedherein which are subject to change without prior notice.

• The information contained in this document has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made asto the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors andrepresentatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document orthe information or opinions contained herein.

• This document contains information on the Company’s markets and competitive position, and more specifically, on the size of its markets. This information has beendrawn from various sources or from the Company’s own estimates which may not be accurate and thus no reliance should be placed on such information.

• This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-lookingstatements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amountsnot yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstancesthat may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company's futureperformance and the Company’s actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materiallyfrom those proposed or reflected in the forward-looking statements contained in this document. Important factors that could cause actual results to differ materially fromthe results anticipated in the forward-looking statements include those discussed or identified in the “Risk Factors” section of our Base Document registered with theAutorité des marchés financiers on March 3, 2014 under number I.14-005 (a copy of which is available on www.genomicvision.com). Even if the Company’s financialposition, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in thisdocument, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertakeany obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect anevent or circumstance that may occur after the date of this document.

• Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables may notnecessarily equal the sum of the individually rounded figures, amounts or percentages.

• All persons accessing this document must agree to the restrictions and limitations set out above.

2November 2015

http://www.genomicvision.com/



KEY MANAGEMENT TEAM

3

Aaron Bensimon, PhD

Founder, President, CEO & CTO

• Co-inventor of Molecular Combing Technology

• Degree in Molecular Biology; PhD of Weizmann Institute

• Head of Genomic Stability Unit at the Pasteur Institute

Erwan Martin, MBA

Vice President Finance & Corporate Development

• Previously with Syndex (French audit company) and CFO of CytomicsPharmaceuticals

• Degree in Business Administration

• Joined Genomic Vision in 2009

November 2015



INVESTMENT HIGHLIGHTS

4

• Molecular diagnostics company developing tests for

genetic diseases and cancers based on molecular combing

• Strategic alliance with Quest Diagnostics formed in November 2010 and renewed in February 2015

• First test commercialized since 2013 in Europe and

US

• Robust pipeline with 2 major tests scheduled for launch in 2015 and 2016 respectively

• Significant opportunity in rapidly growing oncogenetic testing market, projected to grow to $10B -

$25B by 2020, with Prediction/Detection tests expected to account for 56% of the total (Bloomberg and BoozAllenHamilton)

• Solid portfolio of 130 patents

November 2015

SOLID POSITION IN RAPIDLY GROWING ONCOGENETIC TESTING MARKET

1



MOLECULAR COMBING DETECTS STRUCTURAL VARIATIONS

6

Scale: Large Multi Gene

(3Kbp-1Mbp)

Scale: Chromosome

(1Gbp)

Sequencing

Point Mutations (SNPs)

Scale: Single Gene

(1bp-2Kbp)

Sickle Cell AnemiaCharacterized by point mutation

BRCA2 normal gene

BRCA2 mutated gene

Breast Cancer (BRCA2)Characterized by a large insertion in BRCA2

gene

Trisomy 21 –Down Syndrome

Characterized by three copies of chromosome 21

Molecular Combing

Structural Variations

Fish (1)

Chromosomic aberrations

Notes: (1) Fluorescent in situ hybridization.

November 2015



THE IMPORTANCE OF DETECTING STRUCTURAL VARIATIONS

What are structural variations?

Detecting structural variations dramatically improves clinical diagnostics & prognosis

Most technologies cannot accurately detect structural

variations, corresponding to large genomic

rearrangements (LRs) in the 10Kbp – 1Mbp scale range

Structural variations Scientific evidence

Structural variations (SVs) have a strong clinical impact

as they are involved in many diseases

• Using Molecular Combing, Dr. Dominique

Stoppa-Lyonnet has detected large genomic

rearrangements representing 15% of

BRCA 1 samples that weren’t detected with

Myriad Genetics sequencing.

• Large rearrangements in the BRCA1 and

BRCA2 genes represent 10% to 20% of

the mutations directly responsible for cases

of hereditary breast cancer cases each year.

7November 2015

MOLECULAR COMBING: PROPRIETARY AND CLINICALLY-VALIDATED TECHNOLOGY

2



UNIQUE PROPRIETARY TECHNOLOGY

Applying morse code to the genome to enable clearcut diagnostics interpretation

• A fluorescent barcode along the combed DNA molecules automatically identifies and interprets complex, often hidden, structural variationsGenomic

MorseCode

2

BRCA2 normal gene

BRCA2 mutated gene

10kb

Treated glass surface immersed in a solution with naturally-occuring DNA molecule

Single DNA molecule attached and streched on the glass surface

Hundreds of copies of combed DNA molecule from a single patient allowing quantitative analysis

Molecular Combing

1Extracting and stretching single DNA molecule

• DNA is stretched across and attached to a specially-treated glass surface

• User-friendly technology for single-molecule analysis of patient DNA

9November 2015



COMPREHENSIVE OFFERING: PLATFORM AND PRODUCTS

Genomic Vision’s platform

Molecular Combing System

Scanner

Hybridizers

CombHeliX® FSDH Software

Genomic Vision’s consumables

CombHeliX® FSDH probes

Silanized coverslips

DNA Extraction kits

Disposable reservoirs

10November 2015



FULLY INTEGRATED AND PROTECTED WORKFLOW

Initial IP filed by Aaron Bensimon’s team at Institut Pasteur

FROM TO

Combing Image Acq.

HybridizationExtraction Image Anal.

11

Robust, 130-patent portfolio supporting all steps of the Genomic Combing workflow:

Extraction, Combing, Hybridization and Image Acquisition and Analysis

November 2015



GENOMIC VISION’S TECHNOLOGY

12

• The molecular combing technology suitable for population-studies (cohort size in concordance with the biomarker discovery market requirements)

• Genetic Morse Code allows for the target of multiple genes without need of running whole genome analysis

• GV current technology also offers a solid answer to tandem repeats and large CNVs analysis, in particular for organization and allele/phasing

• Current technology offers an attractive answer to structural variations analysis, in particular on SV complexity, highly flexible design of probes

November 2015



GENOMIC VISION’S ADVANTAGES

• BioNano Genomics & Nabsys: a whole genome approach, not allowing to analyze large cohort size

• BioNano Genomics & Nabsys: methods not user-define => not suitable for targeted genes

– Nabsys: uses universal probes (not locus specific probes)

– BNG: uses whole genome nicking enzyme (only 2 enzymes validated)

• Nanostring: a “digitally” counting methodology that limits them to analyze only CNV

– Well positioned in multigene analysis (up to 800 loci)

– The technology can not characterize SVs complexity

– Can analyze CNVs and known fusions but not detect insertion, inversion and translocations

Competitors addressing Structural Variations are not as well positioned to enable Biomarkers discovery

13November 2015

STRATEGIC ALLIANCE WITH QUEST DIAGNOSTICS

3



STRATEGIC PARTNERSHIP

Strategic alliance with Quest Diagnostics

the leader of the U.S. diagnostics market,

signed in November 2010

R&D funding

1

• Funding of internal development

• Development of lab-developed tests (LDTs) used by Quest

Commercial license

2

• Exclusive license for commercialization

in the USA for:

– FSHD test: launched in August 2013

– BRCA test (launching 4Q15)

– HNPCC test (launching 2016)

– SMA

Equity investment

3

• 14.0% stake in Genomic Vision post-IPO

(21.3% pre-IPO)

• Board member

15November 2015



RENEWAL OF STRATEGIC ALLIANCE WITH QUEST DIAGNOSTICS

16

Advantageous conditions enable Genomic Vision to increase its value-

creation potential in new indications with new diagnostics players in the US

• Partnership renewed for 3 more years until November 2018

• No opt-in right for Quest on new tests developed by Genomic Vision

• Genomic Vision has the right to develop and market new tests with other partners, including in the USA (Quest keeps exclusivity on the 4 initial tests)

• Substantial increase in royalty rate

New agreement effective since end-2014

November 2015

DIFFERENTIATED EXPANSION STRATEGY IN KEY GENETIC TESTING MARKETS

4



STRATEGIC DEVELOPMENT

Potential patient population

Proof of concept

Blockbuster

/

Game changer

BRCA

HPV & SMA

• 1st test commercialized

• Hereditary predisposition

• Large population screeningEarly-detection tests

Predisposition tests

Confirmation tests

HNPCC

FSHD

18November 2015



GENOMIC VISION’S STRONG PIPELINE

19

INDICATIONS STATUS LAUNCH MARKET POTENTIAL

MUSCULAR DYSTROPHYFSHD (Facio-Scapulo-Humeral Muscular Dystrophy)

• Launched, routine clinical use 2013 (< $50m)

BREAST CANCER(BRCA 1+2)

• Clinical validation completed

• Industrialization in process2015

(c. $500m in the USc. $2bn global)

COLON CANCERHNPCC / Lynch Syndrome

• Clinical validation on 5 genes completed

• Industrialization in process

2016 (< $100m in US)

CERVICAL CANCERHPV Integration

• Clinical validation in process 2017 (c. $300m)

SMASpinal muscular atrophy • Clinical validation launched - -

November 2015



FSHD: FIRST COMMERCIALIZED DIAGNOSTIC

• FSHD: neuromuscular genetic disease affecting adults and children

• Genomic Vision and Hôpital de La Timone developed an FSHD combing test

• 100% diagnostic sensitivity proven for FSHD combing

• Routinely used in La Timone (250+ per year)

– CE-marked in August 2013

• Commercialized by Quest Diagnostics since August 2013 at Nichols Institute

Molecular Combing test reduces the number of false negatives in FSHD

Clinically validated and already used by practitioners

Proof of concept

20November 2015



BREAST CANCER COMBING TEST: NEXT TEST TO BE LAUNCHED

Note: *Quest Diagnostics press release **Based on Myriad Genetics data, 2013

A demand exists despite little knowledgewithin the population…

… leading to attractive market opportunities

72%of Adult Women in the U.S have never heard of BRCA testing*

58%want to know for sure if they carry

high-risk gene mutations*

20%of women with family history are

undergoing the BRCA tests*

c. $500mEstimated market size in the US**

c. 140,000Tests performed in the US in

2012**

90%Myriad Genetics market share**

Global market size for BRCA is over $2bn**

21November 2015



POTENTIAL SCREENING OF BRCA LARGE REARRANGEMENTS

22

Detection of point mutations in BRCA1 and BRCA2

Patients with strong family history*(Blood sample)

POSITIVE 26% NEGATIVE 74%

100%

POSITIVE (6%) NEGATIVE (68%)

Detection of large rearrangements -

BRCA Combing test

BRCA point mutation positive-

Established genetic statue

Source: 2008, Dalla Palma et al, The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high risk breast cancer families, Cancer Res.

*Note: in none-Ashkenazi Jewish US population

BRCA combing test targeting large rearrangements detection in all the negative samples

November 2015



HPV COMBING TEST: A “GAME CHANGER”

HPV Combing test to avoid invasive and expensive colposcopies:

• Distinguishes high-or low-risk patients

• Avoids useless invasive colposcopies

• Lowers cost to healthcare providers

23

50% of women tested positive with a conventional HPV test do not require colposcopy

ROUTINE PAP-SMEAR

Pos

Wait 1 yearRedo pap-smear

COLPOSCOPY

Clear cut resultsAmbiguous results

HPV Test HPV +

NegHPV Combing

Test

HPV -

ESTIMATED SCREENING MARKET

Women population 86.7 millions

Nb. of colposcopies per year

1.2 million

84.4 millions

1.3 million

50% 50%

November 2015



• A consortium of 8 international participants to share a €6 million grant until 2019

• Genomic Vision’s mission:

– To bring its industrial experience in the detection of structural variations involved in SMA

– To develop a test capable of identifying “2+0” carriers (carriers of both copies of the SMN 1 gene on a chromosome), which are undetectable using existing techniques

GENOMIC VISION SELECTED FOR THE HORIZON 2020 PROGRAM’S ‘BEYONDSEQ’ PROJECT WORTH €6 MILLION

A European Commission project aiming to bridge the technological gap between cytogenetic diagnostics (chromosomal aberrations) and next generation sequencing (single base-pair mutations)

24

Genomic Vision to benefit from the academic know-how in order to drive

its technology towards a new generation of molecular combing

IMPASARA Ltd.

November 2015



COMMERCIALIZATION STRATEGY IN THE US AND IN EUROPE

Two commercialization strategies for two different regions

Combined sales strategy

Direct Partnering

Current

testsFSHD, BRCA,

HNPCC

Low/medium

volume

Direct sales

to specialized

labs

Hospitals,

reference labs,

medical

research labs

Future

testsHPV, SMA

High volume

Collaboration and license to

an industrial partner

25

* The Clinical Laboratory Improvement Amendments (CLIA) of 1988 are federal regulatory standards that apply to all clinical

laboratory testing performed on humans in the United States (with the exception of clinical trials and basic research). Source: aafp

Alliance with Quest and new potential partners

Future

testsNew indications

Collaboration and license to

new potential partners

Other partners

Tests from

the initial

agreement

FSHD, BRCA,

HNPCC, SMA

Exclusive

license to

Quest

Diagnostics

Revenues:

Royalties

CLIA*

laboratories

November 2015



KEY DEVELOPMENTS SINCE THE IPO

26

Full execution of the strategy outlined at IPO

April2014

August2014

September 2014

November 2014

December 2014

IPO

January2015

Presentation of the first

results of the HPV

detection testat the 2014

HPV Conference in

Seattle

Reinforcing the

management

• Head of Business Development

• Head of Bio-informatics /IT

• Head of HR

Commercial team set up

• David del Bourgoappointed Head of Sales & Marketing

• Setting up of a team of Sales and Marketing specialists

2014 annual revenue

from sales at €3.5 million

Solid cash position of

€22.8 million

Renewal of the strategic collaboration with Quest Diagnostics for 3 more

years

Clinical partnership with ROUEN University

Hospital for the SMA

diagnostics test

development in France

BRCA Milestone

with Quest Diagnostics

Installation of the high-throughput genome analyzer

with the new BRCA protocol at Nichols Institute

Further milestones

reached with Quest

• New version of the software for analyzing and interpreting images

• Validation of software to analyze HNPCC test results

Cash position of €18 million

February2015

November 2015

15 October 2015

22 October 2015



SUBSTANTIAL NEWSFLOW IN Q4 2015 / EARLY 2016

27

COMMERCIAL DEVELOPMENT

IN EUROPE

4

• Establishment of the molecular combing platform in new diagnostics centers

BRCA TEST(breast cancer predisposition)

3

• Launch by Quest Diagnostics in the US

HNPCC TEST(colon cancer predisposition)

• Validation and LDT development at Quest Diagnostics

2

SMA TEST(carrier screening)

• Enrolment of the first patients in the clinical study with CHU Rouen

1

November 2015



Q3 2015 FINANCIAL INFORMATION

• Change in Q3 and 9-month 2015 revenue

• Cash position of €18 million at September 30, 2015

– Includes reimbursement of 1.3 million in tax credits

Unaudited data, IFRS

28November 2015

In € thousands 9 months 3rd quarter

2015 2014 2015 2014

Revenue from Quest Diagnostics R&D 1,130 2,857 615 395

Product Sales 242 163 66 69

Total revenue from activity 1,372 3,020 681 464

Other revenue 1,050 858 305 209

Total revenue from activity 2,422 3,878 986 673

For more information visit:

www.genomicvision.com

APPENDICES



GENOMIC VISION & THE STOCK EXCHANGE

31

• IPO date: April 2nd, 2014

• Market: Euronext in Paris (compartment C)

• Share price: €10.00 (October 30th, 2015)

• High: €15.86 (March 2nd, 2015)

• Low: €9.90 (October 13th, 2015)

• Number of shares: 4,457,734

• Market Cap: €45m (October 30th, 2015)

• Average daily trading: 7,346 shares since the IPO

Shareholding structure (As of 31.10.2015)Stock market information

Stock codes

• Name: GENOMIC VISION

• Mnemonic: GV

• ISIN code: FR0011799907

• Member of CAC® Mid & Small and CAC® All-Tradable indexes

Contacts

Genomic Vision

Aaron Bensimon – CEO / Erwan Martin – CFO

Tel: +33 1 49 08 07 40

E-mail: [email protected]

Website: www.genomicvision.com

Investor Relations & Strategic Communications

Emmanuel Huynh / Dusan Oresansky

Tel: +33 1 44 71 94 93

E-mail: [email protected]

November 2015

10,1%

3,6%

13,8%72,4%

0,2% Management, founders &employees

Institut Pasteur

Quest Diagnostic

Free Float

Autocontrôle

mailto:[email protected]

http://ipo.genomicvision.com/

mailto:[email protected]



H1 2015 FINANCIAL INFORMATION

32

In € thousands 30.06.2015 30.06.2014

Total revenue from activity 1,436 3,206

of which sales 691 2,557

R&D expenses (1,913) (2,337)

Net income (loss) (2,208) (310)

In € thousands 30.06.2015 31.12.2014

Shareholder’s equity 20,621 22,695

Financial debt 599 792

Cash and cash equivalents 18,734 22,764

Operating cash flow (2,868) (3,771)

Audited data, IFRS

November 2015



KEY 2014 FINANCIALS

33

In € thousands 31.12.2014 31.12.2013

Total revenue from activity 4,893 4,039

of which sales 3,455 2,887

R&D expenses (4,354) (3,453)

Net income (loss) (2,156) (1,069)

In € thousands 31.12.2014 31.12.2013

Shareholder’s equity 22,695 982

Financial debt 792 824

Cash and cash equivalents 22,764 3,226

Operating cash flow (3,771) 243

Audited data, IFRS

November 2015

Documents

Molecular combing technology Facts & figures Lucia Cinque, …...oncogenetic testing market, projected to grow to $10B - $25B by 2020, with Prediction/Detection tests expected to account